Foal IgG and opsonizing anti-Rhodococcus equi antibodies after immunization of pregnant mares with a protective VapA candidate vaccine
- PMID: 15530741
- DOI: 10.1016/j.vetmic.2004.09.006
Foal IgG and opsonizing anti-Rhodococcus equi antibodies after immunization of pregnant mares with a protective VapA candidate vaccine
Abstract
The aim of this study was to evaluate serum IgG antibody levels and opsonizing activity in foals from pregnant mares immunized with either proteins from an R. equi strain containing virulence-associated protein A (VapA), an immunodominant surface-expressed lipoprotein encoded by a virulence plasmid crucial for virulence in foals, or a whole killed virulent R. equi preparation. Forty-eight pregnant mares were distributed into three groups, i.e. 24 immunized with R. equi VapA protein antigen associated with a water-based nanoparticle adjuvant (Montanide IMS 3012), 8 immunized with whole killed R. equi, and 16 non-immunized as control. Serum IgG and opsonizing capacity were evaluated during pregnancy in mares, and up to day 45 post-delivery in foals in which R. equi infections were recorded in the first 6 months of life. Pregnant mares immunized with virulent R. equi proteins developed higher serum IgG and opsonic activity which were transferred to the foals than either in the whole R. equi immunized or the control group. Four foals developed pneumonia in the control group while none in immunized groups. Results support further evaluation of VapA protein antigen associated with a water-based nanoparticle adjuvant as a candidate vaccine for immunization of pregnant mares resulting in passive antibody-mediated protection of foals.
Similar articles
-
Use of Rhodococcus equi virulence-associated protein for immunization of foals against R equi pneumonia.Am J Vet Res. 1997 Apr;58(4):356-9. Am J Vet Res. 1997. PMID: 9099378 Clinical Trial.
-
Assessment in mice of vapA-DNA vaccination against Rhodococcus equi infection.Vet Immunol Immunopathol. 2005 Apr 8;104(3-4):215-25. doi: 10.1016/j.vetimm.2004.12.006. Vet Immunol Immunopathol. 2005. PMID: 15734542
-
Immunogenecity of synthetic peptides representing linear B-cell epitopes of VapA of Rhodococcus equi.Vaccine. 2004 Mar 12;22(9-10):1114-23. doi: 10.1016/j.vaccine.2003.10.006. Vaccine. 2004. PMID: 15003638
-
Rhodococcus equi.Vet Res. 2004 Jul-Aug;35(4):383-96. doi: 10.1051/vetres:2004024. Vet Res. 2004. PMID: 15236672 Review.
-
Rhodococcus equi (Prescottella equi) vaccines; the future of vaccine development.Equine Vet J. 2015 Sep;47(5):510-8. doi: 10.1111/evj.12310. Epub 2014 Sep 14. Equine Vet J. 2015. PMID: 24945608 Review.
Cited by
-
Oral Administration of Electron-Beam Inactivated Rhodococcus equi Failed to Protect Foals against Intrabronchial Infection with Live, Virulent R. equi.PLoS One. 2016 Feb 1;11(2):e0148111. doi: 10.1371/journal.pone.0148111. eCollection 2016. PLoS One. 2016. PMID: 26828865 Free PMC article.
-
Antibody activities in hyperimmune plasma against the Rhodococcus equi virulence -associated protein A or poly-N-acetyl glucosamine are associated with protection of foals against rhodococcal pneumonia.PLoS One. 2021 Aug 26;16(8):e0250133. doi: 10.1371/journal.pone.0250133. eCollection 2021. PLoS One. 2021. PMID: 34437551 Free PMC article.
-
The type of anticoagulant used for plasma collection affects in vitro Rhodococcus equi assays.BMC Res Notes. 2022 Feb 14;15(1):50. doi: 10.1186/s13104-022-05933-4. BMC Res Notes. 2022. PMID: 35164828 Free PMC article.
-
An inventory of adjuvants used for vaccination in horses: the past, the present and the future.Vet Res. 2023 Mar 2;54(1):18. doi: 10.1186/s13567-023-01151-3. Vet Res. 2023. PMID: 36864517 Free PMC article. Review.
-
The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies.Mol Immunol. 2008 Feb;45(3):818-27. doi: 10.1016/j.molimm.2007.06.158. Epub 2007 Jul 31. Mol Immunol. 2008. PMID: 17669496 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources